A Phase II Study of Neoadjuvant FOLFIRINOX

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 3, 2014

Primary Completion Date

February 14, 2018

Study Completion Date

October 28, 2019

Conditions
Resectable Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

FOLFIRINOX

"FOLFIRINOX consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."

Trial Locations (1)

46202

Indiana University Simon Cancer Center, Indianapolis

All Listed Sponsors
lead

Indiana University

OTHER

NCT02178709 - A Phase II Study of Neoadjuvant FOLFIRINOX | Biotech Hunter | Biotech Hunter